Chapter 35 Prospectives for cell and gene therapy in Huntington's disease

[1]  Françoise Condé,et al.  Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease , 1998, Nature Medicine.

[2]  S. Palfi,et al.  Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats , 1997, Neuroscience.

[3]  D. Riche,et al.  Riluzole Reduces Incidence of Abnormal Movements but Not Striatal Cell Death in a Primate Model of Progressive Striatal Degeneration , 1997, Experimental Neurology.

[4]  M. Hayden,et al.  The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. , 1997, American journal of human genetics.

[5]  M. Peschanski,et al.  Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease , 1997, Nature.

[6]  B. Davidson,et al.  Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy , 1997, Science.

[7]  M. Peschanski,et al.  Long-term histological follow-up of genetically modified myoblasts grafted into the brain. , 1997, Brain research. Molecular brain research.

[8]  M. Peschanski,et al.  Adenovirus-mediated gene transfer to the brain: methodological assessment , 1997, Journal of Neuroscience Methods.

[9]  R. Penn,et al.  Intrathecal Ciliary Neurotrophic Factor Delivery for Treatment of Amyotrophic Lateral Sclerosis (Phase I Trial) , 1997 .

[10]  C. Benoist,et al.  A powerful nonviral vector for in vivo gene transfer into the adult mammalian brain: polyethylenimine. , 1996, Human gene therapy.

[11]  F. Gage,et al.  Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[12]  E. Mufson,et al.  Functional fetal nigral grafts in a patient with Parkinson's disease: Chemoanatomic, ultrastructural, and metabolic studies , 1996, The Journal of comparative neurology.

[13]  Myriam Schluep,et al.  Intrathecal delivery of CNTF using encapsulated genetically modifiedxenogeneic cells in amyotrophic lateral sclerosis patients , 1996, Nature Medicine.

[14]  N. Déglon,et al.  Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF. , 1996, Human gene therapy.

[15]  M. Beal,et al.  Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington’s Disease , 1996, The Journal of Neuroscience.

[16]  F. Gage,et al.  Grafts of fibroblasts genetically modified to secrete NGF, BDNF, NT-3, or basic FGF elicit differential responses in the adult spinal cord. , 1996, Cell transplantation.

[17]  O. Lindvall,et al.  Core assessment program for intracerebral transplantation in Huntington's disease (CAPIT‐HD) , 1996, Movement disorders : official journal of the Movement Disorder Society.

[18]  C. Olanow,et al.  Fetal nigral transplantation as a therapy for Parkinson's disease , 1996, Trends in Neurosciences.

[19]  Y. Samson,et al.  Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. , 1996, Brain : a journal of neurology.

[20]  C. Ross,et al.  Neurobiology of Huntington's Disease , 1996, Neurobiology of Disease.

[21]  Jane S. Paulsen,et al.  Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.

[22]  I. Shoulson,et al.  A prospective evaluation of cognitive decline in early Huntington's disease , 1995, Neurology.

[23]  Vincent Frouin,et al.  Clinical correlates of {18F}fluorodopa uptake in five grafted Parkinsonian patients , 1995, Annals of neurology.

[24]  F. Vingerhoets,et al.  Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease , 1995, Annals of neurology.

[25]  M. Peschanski,et al.  Effects of target deprivation on the morphology and survival of adult dorsal column nuclei neurons , 1995, The Journal of comparative neurology.

[26]  P R Sanberg,et al.  Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. , 1995, The New England journal of medicine.

[27]  A. Björklund,et al.  Neurotransmitter-related gene expression in intrastriatal striatal transplants—II. Characterization of efferent projecting graft neurons , 1995, Neuroscience.

[28]  J. Gusella,et al.  Huntington's disease. , 1995, Seminars in cell biology.

[29]  F. Hefti.  Neurotrophic factor therapy for nervous system degenerative diseases. , 1994, Journal of neurobiology.

[30]  M. Peschanski,et al.  Fine structural alteration in target-deprived axonal terminals in the rat thalamus , 1994, Neuroscience.

[31]  M. Peschanski,et al.  Target dependence of adult neurons: pattern of terminal arborizations , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[32]  Y. Samson,et al.  Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. , 1994, Brain : a journal of neurology.

[33]  Richard S. J. Frackowiak,et al.  Evidence for long‐term survival and function of dopaminergic grafts in progressive Parkinson's disease , 1994, Annals of neurology.

[34]  Stephen B. Dunnett,et al.  Functional neural transplantation , 1994 .

[35]  J. Coyle,et al.  Oxidative stress, glutamate, and neurodegenerative disorders. , 1993, Science.

[36]  M. Sasaki,et al.  Cerebral glucose metabolism and striatal 18F-Dopa uptake by PET in cases of chorea with or without dementia , 1993, Journal of the Neurological Sciences.

[37]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[38]  M. Peschanski,et al.  Catecholaminergic neurons result from intracerebral implantation of embryonal carcinoma cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[39]  E. R. Kandel,et al.  Synaptic transmission: A bidirectional and self-modifiable form of cell-cell communication , 1993, Cell.

[40]  M. Perricaudet,et al.  Transfer of a foreign gene into the brain using adenovirus vectors , 1993, Nature Genetics.

[41]  Scott T. Grafton,et al.  Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. , 1992, The New England journal of medicine.

[42]  A. Björklund,et al.  Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) , 1992, The New England journal of medicine.

[43]  D. Spencer,et al.  Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. , 1992, The New England journal of medicine.

[44]  M. Peschanski,et al.  Host dopaminergic afferents affect the development of DARPP-32 immunoreactivity in transplanted embryonic striatal neurons , 1992, Neuroscience.

[45]  D. Riche,et al.  Intrastriatal transplantation of cross-species fetal striatal cells reduces abnormal movements in a primate model of Huntington disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[46]  T. Robbins,et al.  Striatal Graft‐Associated Recovery of a Lesion‐Induced Performance Deficit in the Rat Requires Learning to Use The Transplant , 1992, The European journal of neuroscience.

[47]  Richard S. J. Frackowiak,et al.  Transplantation of fetal dopamine neurons in Parkinson's disease: PET {18F}6‐L‐fluorodopa studies in two patients with putaminal implants , 1992, Annals of neurology.

[48]  Richard S. J. Frackowiak,et al.  Transplantation of fetal dopamine neurons in Parkinson's disease: One‐year clinical and neurophysiological observations in two patients with putaminal implants , 1992, Annals of neurology.

[49]  D. Brooks,et al.  Core assessment program for intracerebral transplantations (CAPIT) , 1992, Movement disorders : official journal of the Movement Disorder Society.

[50]  A. Björklund,et al.  Development of intrastriatal striatal grafts and their afferent innervation from the host , 1991, Neuroscience.

[51]  D. Salmon,et al.  The nature of the naming deficit in Alzheimer's and Huntington's disease. , 1991, Brain : a journal of neurology.

[52]  C. Clough,et al.  Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease. , 1991, Archives of neurology.

[53]  D. Sax,et al.  Factors associated with slow progression in Huntington's disease. , 1991, Archives of neurology.

[54]  R. S. Williams,et al.  Morphometric analysis of the prefrontal cortex in Huntington's disease , 1991, Neurology.

[55]  C. Randolph.  Implicit, explicit, and semantic memory functions in Alzheimer's disease and Huntington's disease. , 1991, Journal of clinical and experimental neuropsychology.

[56]  Y. Agid,et al.  Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsy , 1991, Neurology.

[57]  C. Wilson,et al.  Synaptic potentials evoked in spiny neurons in rat neostriatal grafts by cortical and thalamic stimulation. , 1991, Journal of neurophysiology.

[58]  Peter S. Harper,et al.  Huntington's disease , 1991 .

[59]  J. Bennett,et al.  Fetal neostriatal transplants in the rat: A light and electron microscopic Golgi study , 1990, Neuroscience.

[60]  A. Björklund,et al.  Fetal striatal neurons grafted into the ibotenate lesioned adult striatum: Efferent projections and synaptic contacts in the host globus pallidus , 1990, Neuroscience.

[61]  N Butters,et al.  Differential impairment of semantic and episodic memory in Alzheimer's and Huntington's diseases: a controlled prospective study. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[62]  Scott T. Grafton,et al.  A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease , 1990, Annals of neurology.

[63]  V. Bracha,et al.  Unilateral striatal grafts induce behavioral and electrophysiological asymmetry in rats with bilateral kainate lesions of the caudate nucleus. , 1990, Behavioral neuroscience.

[64]  H. Herzog,et al.  Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. , 1990, Brain : a journal of neurology.

[65]  D. Salmon,et al.  Pictorial priming and cued recall in Alzheimer's and Huntington's disease , 1990, Brain and Cognition.

[66]  Scott T. Grafton,et al.  Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year. , 1990, Archives of neurology.

[67]  C D Marsden,et al.  Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. , 1990, Science.

[68]  M. Cudkowicz,et al.  Degeneration of pyramidal projection neurons in Huntington's disease cortex , 1990, Annals of neurology.

[69]  A. Björklund,et al.  Connectivity of striatal grafts implanted into the ibotenic acid-lesioned striatum—III. Efferent projecting graft neurons and their relation to host afferents within the grafts , 1989, Neuroscience.

[70]  L. Thal,et al.  Differentiation of Alzheimer's disease and Huntington's disease with the Dementia Rating Scale. , 1989, Archives of neurology.

[71]  J. Illes.  Neurolinguistic features of spontaneous language production dissociate three forms of neurodegenerative disease: Alzheimer's, Huntington's, and Parkinson's , 1989, Brain and Language.

[72]  D. Salmon,et al.  A comparison of the category fluency deficits associated with Alzheimer's and Huntington's disease , 1989, Brain and Language.

[73]  M. Giordano,et al.  Fetal striatal tissue grafts into excitotoxin-lesioned striatum: Pharmacological and behavioral aspects , 1989, Pharmacology Biochemistry and Behavior.

[74]  Hitoshi Takahashi,et al.  A quantitative investigation of the substantia nigra in Huntington's disease , 1989, Annals of neurology.

[75]  Richard S. J. Frackowiak,et al.  PET and movement disorders. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[76]  S. Plumb,et al.  A controlled clinical trial of baclofen as protective therapy in early huntington's disease , 1989, Annals of neurology.

[77]  D. Salmon,et al.  Neuropsychological evidence for multiple implicit memory systems: a comparison of Alzheimer's, Huntington's, and Parkinson's disease patients , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[78]  E. Eidelberg,et al.  Transsynaptic degeneration of motoneurones caudal to spinal cord lesions , 1989, Brain Research Bulletin.

[79]  E. Granholm,et al.  Retrograde amnesia in patients with Alzheimer's disease or Huntington's disease , 1988, Neurobiology of Aging.

[80]  J. Noth,et al.  Language functions in Huntington's disease. , 1988, Brain : a journal of neurology.

[81]  A. Björklund,et al.  Connectivity of striatal grafts implanted into the ibotenic acid-lesioned striatum—I. Subcortical afferents , 1988, Neuroscience.

[82]  M. Peschanski,et al.  Morphological alteration of thalamic afferents in the excitotoxically lesioned striatum , 1988, Brain Research.

[83]  P. Sharp,et al.  Imaging of cerebral blood flow markers in Huntington's disease using single photon emission computed tomography. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[84]  X. Breakefield,et al.  A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. , 1988, Science.

[85]  J. Vonsattel,et al.  Morphometric Demonstration of Atrophic Changes in the Cerebral Cortex, White Matter, and Neostriatum in Huntington's Disease , 1988, Journal of neuropathology and experimental neurology.

[86]  E. Granholm,et al.  Associative encoding and retrieval in Alzheimer's and Huntington's disease , 1988, Brain and Cognition.

[87]  S. Folstein,et al.  Differential cognitive impairment in alzheimer's disease and huntington's disease , 1988, Annals of neurology.

[88]  R. Hichwa,et al.  Positron emission tomographic scan investigations of Huntington's disease: Cerebral metabolic correlates of cognitive function , 1988, Annals of neurology.

[89]  S. P. Hunt,et al.  Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea , 1988, Neuroscience.

[90]  A. Björklund,et al.  Striatal grafts in rats with unilateral neostriatal lesions—I. Ultrastructural evidence of afferent synaptic inputs from the host nigrostriatal pathway , 1988, Neuroscience.

[91]  A. Björklund,et al.  Striatal grafts in rats with unilateral neostriatal lesions—III. Recovery from dopamine-dependent motor asymmetry and deficits in skilled paw reaching , 1988, Neuroscience.

[92]  A. Björklund,et al.  Striatal grafts in rats with unilateral neostriatal lesions—II. In vivo monitoring of gaba release in globus pallidus and substantia nigra , 1988, Neuroscience.

[93]  M. Giordano,et al.  Striatal tissue transplants attenuate apomorphine-induced rotational behavior in rats with unilateral kainic acid lesions , 1988, Neuropharmacology.

[94]  D. Weinberger,et al.  Prefrontal cortical blood flow and cognitive function in Huntington's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[95]  M. Garcia-Munoz,et al.  Electrophysiological demonstration of host cortical inputs to striatal grafts , 1987, Neuroscience Letters.

[96]  M. Giordano,et al.  Multiple Transplants of Fetal Striatal Tissue in the Kainic Acid Model of Huntington's Disease , 1987 .

[97]  J. Besson,et al.  Structural alteration and possible growth of afferents after kainate lesion in the adult rat thalamus , 1987, The Journal of comparative neurology.

[98]  J. Mazziotta,et al.  Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. , 1987, The New England journal of medicine.

[99]  M. Hayden,et al.  Positron emission tomography in the early diagnosis of Huntington's disease , 1986, Neurology.

[100]  P. Sanberg,et al.  Locomotor hyperactivity: Effects of multiple striatal transplants in an animal model of Huntington's disease , 1986, Pharmacology Biochemistry and Behavior.

[101]  A. Björklund,et al.  Graft-induced behavioral recovery in an animal model of Huntington disease. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[102]  R. Robinson,et al.  Behavioral recovery following kainic acid lesions and fetal implants of the striatum occurs independent of dopaminergic mechanisms , 1986, Brain Research.

[103]  C D Marsden,et al.  Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography , 1986, Movement disorders : official journal of the Movement Disorder Society.

[104]  M. C. Zemanick,et al.  Morphology of embryonic neostriatal cell suspensions transplanted into adult neostriata. , 1985, Brain research.

[105]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[106]  F. Gage,et al.  Functional neuronal replacement by grafted striatal neurones in the ibotenic acid-lesioned rat striatum , 1984, Nature.

[107]  A. Young,et al.  A polymorphic DNA marker genetically linked to Huntington's disease , 1983, Nature.

[108]  J. Coyle,et al.  Reversal of long-term locomotor abnormalities in the kainic acid model of Huntington's disease by day 18 fetal striatal implants. , 1983, European journal of pharmacology.

[109]  C. Markham,et al.  Cerebral metabolism and atrophy in huntington's disease determined by 18FDG and computed tomographic scan , 1982, Annals of neurology.

[110]  K. F. Schroeder,et al.  Morphometric studies of the neuropathological changes in choreatic diseases , 1976, Journal of the Neurological Sciences.

[111]  R. Dom,et al.  Neuropathology of Huntington's chorea , 1976, Neurology.